Safety and anti-tumor activity of Pasireotide in patients with BRAF- and NRAS-wild type, unresectable and or metastatic melanoma: a phase I, open-label, single-arm study

被引：0
|
作者：
Schadendorf, D. [1 ]
Michielin, O. [2 ,3 ]
Nageli, M. [4 ]
Goldinger, S. M. [4 ]
Campigotto, F. [5 ]
Kriemler-Krahn, U. [6 ]
Schmid, H. A. [6 ]
Pedroncelli, A. M. [6 ]
Micaletto, S. [4 ]
Dummer, R. [4 ]
机构：
[1] Univ Hosp Essen, Dept Dermatol, Essen, Germany
[2] Lausanne Univ Hosp CHUV, Multidisciplinary Oncol Ctr, Lausanne, Switzerland
[3] Swiss Inst Bioinformat SIB, Lausanne, Switzerland
[4] Univ Zurich Hosp, Dept Dermatol, Zurich, Switzerland
[5] Novartis Pharmaceut, E Hanover, NJ USA
[6] Novartis Pharmaceut AG, Basel, Switzerland
来源：
MELANOMA RESEARCH | 2016年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P064
引用
收藏
页码：E43 / E44
页数：2
相关论文
共 50 条
  • [11] A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma in the United States
    Flaherty, Lawrence
    Hamid, Omid
    Linette, Gerald
    Schuchter, Lynn
    Hallmeyer, Sigrun
    Gonzalez, Rene
    Cowey, C. Lance
    Pavlick, Anna
    Kudrik, Fred
    Curti, Brendan
    Lawson, David
    Chapman, Paul B.
    Margolin, Kim
    Ribas, Antoni
    McDermott, David
    Flaherty, Keith
    Cranmer, Lee
    Hodi, F. Stephen
    Day, Bann-Mo
    Linke, Rolf
    Hainsworth, John
    CANCER JOURNAL, 2014, 20 (01): : 18 - 24
  • [12] A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer
    Xu, Jianming
    Bai, Yuxian
    Sun, Huichuan
    Bai, Chunmei
    Jia, Ru
    Li, Yi
    Zhang, Wenjie
    Liu, Lei
    Huang, Cheng
    Guan, Mei
    Zhou, Jinghong
    Su, Weiguo
    CANCER, 2021, 127 (21) : 3975 - 3984
  • [13] A multicenter, open-label, single-arm, phase 1 dose-escalation study to evaluate the safety, tolerability, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1
    Hu, Xiaojie
    Zeng, Kang
    Xu, Zhongyuan
    Li, Wenbin
    Li, Changxing
    Kang, Zhuang
    Li, Shenglan
    Hui, Ai-Min
    Wu, Zhuli
    Huang, Xin
    Han, Pu
    Ben Li
    Lin, Xiaoxi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [14] A single-arm, open-label, phase II study to evaluate the safety of vemurafenib (VEM) followed by ipilimumab (IPI) in BRAF V600-mutated metastatic melanoma (MM).
    Amin, Asim
    Lawson, David H.
    Salama, April K.
    Koon, Henry B.
    Guthrie, Troy H.
    Thomas, Sajeve Samuel
    O'Day, Steven
    Shaheen, Montaser F.
    Zhang, Bin
    Francis, Stephen
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [15] ASO Visual Abstract: Efficacy and Safety of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter, Phase 3 Study
    Zager, Jonathan S.
    Orloff, Marlana
    Ferrucci, Pier Francesco
    Choi, Junsung
    Eschelman, David J.
    Glazer, Evan S.
    Ejaz, Aslam
    Howard, J. Harrison
    Richtig, Erika
    Ochsenreither, Sebastian
    Reddy, Sunil A.
    Lowe, Michael C.
    Beasley, Georgia M.
    Gesierich, Anja
    Bender, Armin
    Gschnell, Martin
    Dummer, Reinhard
    Rivoire, Michel
    Arance, Ana
    Fenwick, Stephen William
    Sacco, Joseph J.
    Haferkamp, Sebastian
    Weishaupt, Carsten
    John, Johnny
    Wheater, Matthew
    Ottensmeier, Christian H.
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (08) : 5220 - 5221
  • [16] A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer.
    Bai, Yuxian
    Xu, Jianming
    Sun, Huichuan
    Bai, Chunmei
    Jia, Ru
    Li, Yi
    Zhang, Wenjie
    Liu, Lei
    Huang, Cheng
    Guan, Mei
    Zhou, Jinghong
    Su, Weiguo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [17] Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
    Zimmer, Lisa
    Eigentler, Thomas K.
    Kiecker, Felix
    Simon, Jan
    Utikal, Jochen
    Mohr, Peter
    Berking, Carola
    Kaempgen, Eckhart
    Dippel, Edgar
    Stadler, Rudolf
    Hauschild, Axel
    Fluck, Michael
    Terheyden, Patrick
    Rompel, Rainer
    Loquai, Carmen
    Assi, Zeinab
    Garbe, Claus
    Schadendorf, Dirk
    JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13
  • [18] Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
    Lisa Zimmer
    Thomas K. Eigentler
    Felix Kiecker
    Jan Simon
    Jochen Utikal
    Peter Mohr
    Carola Berking
    Eckhart Kämpgen
    Edgar Dippel
    Rudolf Stadler
    Axel Hauschild
    Michael Fluck
    Patrick Terheyden
    Rainer Rompel
    Carmen Loquai
    Zeinab Assi
    Claus Garbe
    Dirk Schadendorf
    Journal of Translational Medicine, 13
  • [19] Fanconi anemia repair pathway as a predictor of anti-tumor activity of pembrolizumab: interim analysis of open-label, single-arm phase II trial
    Diaz, John
    Duan, Wenrui
    Gatcliffe, Troy
    Diaz, Zuanel
    Schroeder, Eric
    Lambrou, Nicholas
    Eiseler, Nicole
    Morrissey, Thomas
    Villalona-Calero, Miguel
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S66 - S67
  • [20] Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial
    Song, Zhengbo
    Lou, Guangyuan
    Wang, Yina
    Yang, Zhiping
    Wang, Wenxian
    Ji, Yongling
    Chen, Shiqing
    Xu, Chunwei
    Hu, Xiao
    Zhang, Yiping
    BMC MEDICINE, 2022, 20 (01)
12345